Want to see TSE:INNO full AI Analyst Report?
INNO Stock Chart & Stats
C$7.50
C$0.01(5.26%)
At close: 4:00 PM EST
C$7.50
C$0.01(5.26%)
Day’s Range― - ―
52-Week RangeC$2.40 - C$21.00
Previous CloseN/A
Volume118.77K
Average Volume (3M)920.00
Market Cap
C$13.95M
Enterprise ValueC$4.95M
Total Cash (Recent Filing)C$6.68M
Total Debt (Recent Filing)C$1.42M
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume392
30 Day Avg. Volume920
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~90% gross margin indicates strong product-level economics and pricing power. Over the medium term this supports scalable unit economics: once operating expenses are controlled, incremental revenue can flow quickly to operating profit, enabling durable profitability if sales resume.
Moderate Leverage / Balance SheetLow relative leverage and a meaningful equity base give the company financing flexibility to fund development and absorb near-term losses. Moderate debt reduces bankruptcy risk and provides runway for product development or strategic partnerships without immediate distress financing.
Proprietary Delivery Tech & Focused PipelineA clear focus on cannabinoid therapeutics and proprietary long-acting delivery approaches creates structural differentiation. Specialized IP and a dual human/veterinary addressable market support licensing, partnerships and niche leadership that can yield durable revenue streams beyond short-term cycles.
Bears Say
Negative Cash Flow / Cash BurnOperating and free cash flow turning negative after prior positive results signals persistent cash burn. Continued negative cash generation forces reliance on external funding or equity raises, which can dilute owners and restrict R&D and commercialization spending until cash flows turn positive.
Revenue SlowdownA reversal from rapid multi-year growth to a TTM revenue decline undermines operating leverage and delays the conversion of high gross margins into sustainable profits. Slower top-line growth increases the risk that fixed operating costs will persistently outpace revenues.
Continued Losses & Negative ReturnsDespite margin strengths, the company remains loss-making with negative ROE and rising debt versus prior years. Negative returns indicate invested capital isn't producing profits, increasing the probability that further financing or restructuring will be required if operating losses persist.
InnoCan Pharma News
INNO FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was C$2.40 and its highest was C$21.00 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is C$13.95M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Aug 31, 2026 which is in 38 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on May 27, 2026. The company reported -C$0.296 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.296.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -C$0.296 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.88%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in TSE:INNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland, France, and various international markets. The company actively pursues research and development into treatments for conditions such as COVID-19, leveraging CBD delivered via exosomes and liposomes. InnoCan's product line features a range of CBD-infused topical items, including eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Beyond R&D, the corporation is also involved in the marketing and distribution of its proprietary CBD-enhanced pharmaceutical and cosmetic offerings. Established in 2018, InnoCan Pharma Corporation maintains its principal office in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―